|
| Tuesday, December 1, 2015 |
|
|
Eisai and Toyama Chemical Clear All-Case Surveillance Condition for Approval of Antirheumatic Agent Iguratimod |
Eisai Co., Ltd. and Fujifilm Group company Toyama Chemical Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) to the effect that the "all-case surveillance" special drug use-results survey condition required for approval of the antirheumatic agent iguratimod has been lifted.
more info >> |
|
|
U.S. FDA Accepts NDA for Once-Daily Formulation of Antiobesity Agent Belviq |
| Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for a once-daily formulation of its antiobesity agent BELVIQ which has the potential to offer patients the convenience of once-daily treatment. more info >> |
|
| Tuesday, November 17, 2015 |
|
|
Successful Ruling in Patent Infringement Litigation for Antiemetic Agent Aloxi in the United States |
Eisai Co., Ltd. announced today that the U.S. District Court for the District of New Jersey has ruled in favor of Helsinn Healthcare S.A. in the patent infringement lawsuit for antiemetic agent ALOXI (palonosetron hydrochloride) brought by Helsinn together with Roche Palo Alto LLC (Roche) against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. in the United States, where it was determined that certain formulation patent claims for ALOXI are valid and infringed.
more info >> |
|
| Thursday, November 5, 2015 |
|
|
Eisai to Commence Two Joint Research Programs toward Development of New Antimalarial Medicines |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has entered into two joint research agreements for the development of new antimalarial medicines. more info >> |
|
| Monday, November 2, 2015 |
|
|
Eisai Presents Results from Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan Oral Presentation Given at 49th Congress of The Japan Epilepsy Society |
| Eisai Co., Ltd. announced today that an oral presentation highlighting results from a Phase III clinical study (Study 335) of its in-house developed antiepileptic drug (AED) perampanel hydrate (global product name: Fycompa) in patients with refractory partial-onset seizures conducted in Asia, including Japan, was given at the 49th Congress of the Japan Epilepsy Society held from October 30 to 31 in Nagasaki, Japan. more info >> |
|
| Monday, October 19, 2015 |
|
|
Phase II Trial Results on Novel Anticancer Agent Lenvima in Renal Cell Carcinoma Published in the Lancet Oncology |
| Eisai Co., Ltd. announced today that the results of a Phase II clinical trial (Study 205) of its in-house developed novel anticancer agent Lenvima in advanced or metastatic renal cell carcinoma have been published in the online version of The Lancet Oncology, a leading clinical oncology research journal that is highly regarded worldwide. more info >> |
|
| Monday, October 5, 2015 |
|
|
Eisai to Provide Diethylcarbamazine Citrate Tablets Free of Charge for Use in National Lymphatic Filariasis Elimination Campaign in Indonesia |
| Eisai Co., Ltd. announced today that it has provided 151 million 100 mg tablets of the lymphatic filariasis treatment diethylcarbamazine citrate (DEC) free of charge for use in mass drug administration (MDA) conducted through the BELKAGA campaign being promoted by the Government of Indonesia. more info >> |
|
| Tuesday, September 29, 2015 |
|
|
Eisai Receives Additional Approval in Japan for Vascular Embolization Device DC Bead as Treatment of Hypervascular Tumors and Arteriovenous Malformations |
| Eisai Co., Ltd. announced today that it has received additional approval for the vascular embolization device DC Bead to be used for the treatment of hypervascular tumors and arteriovenous malformations (AVM) in Japan. more info >> |
|
|
U.S. FDA Grants Priority Review Status to sNDA for Anticancer Agent Halaven as Treatment for Soft Tissue Sarcoma |
| Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's in-house developed anticancer agent Halaven (eribulin mesylate) as a treatment for soft tissue sarcoma, and granted the sNDA Priority Review status. more info >> |
|
| Friday, September 25, 2015 |
|
|
Eisai to Sponsor Lectures at Japan Research Center of Fudan University in China |
| Eisai Co., Ltd announced today that its holding company in China, Eisai China Holdings Ltd., will sponsor lectures at the Japan Research Center of Fudan University, one of China's top academic institutes, in Shanghai. more info >> |
|
|
|
